{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:57:55Z","timestamp":1781323075049,"version":"3.54.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7519-26","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T22:09:50Z","timestamp":1781129390000},"source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod as a Steroid-sparing Therapy for Evans Syndrome: A Case Report"],"prefix":"10.2169","author":[{"given":"Yudai","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Hematology, Kushiro Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Senjo","sequence":"additional","affiliation":[{"name":"Hematology, Kushiro Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Hematology, Kushiro Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Aiba","sequence":"additional","affiliation":[{"name":"Hematology, Kushiro Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Miyagishima","sequence":"additional","affiliation":[{"name":"Hematology, Kushiro Rosai Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. EVANS RS, et al. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med 1951.","DOI":"10.1001\/archinte.1951.03810010058005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 132: 125-137, 2006.","DOI":"10.1111\/j.1365-2141.2005.05809.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fattizzo B, Michel M, Giannotta JA, et al. Evans syndrome in adults: an observational multicenter study. Blood Adv 5: 5468-5478, 2021 Dec 28.","DOI":"10.1182\/bloodadvances.2021005610"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Audia S, Grienay N, Mounier M, et al. Evans' Syndrome: From Diagnosis to Treatment. J Clin Med 9: 3851, 2020.","DOI":"10.3390\/jcm9123851"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jaime-P\u00e9rez JC, Aguilar-Calder\u00f3n PE, Salazar-Cavazos L, et al. Evans syndrome: clinical perspectives, biological insights and treatment modalities. J Blood Med 9: 171-184, 2018.","DOI":"10.2147\/JBM.S176144"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Broome C. Efgartigimod alfa for the treatment of primary immune thrombocytopenia. Ther Adv Hematol 14: 20406207231172831, 2023.","DOI":"10.1177\/20406207231172831"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kamesaki T. Progress in diagnosis and treatment of autoimmune hemolytic anemia. Rinsho Ketsueki 60: 1100-1107, 2019.","DOI":"10.11406\/rinketsu.60.1100"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Kashiwagi H. Reference guide for management of adult idiopathic thrombocytopenic purpura (ITP): 2019 version. Rinsho Ketsueki 60: 877-896, 2019.","DOI":"10.11406\/rinketsu.60.877"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Emilio DS, Vikram R, Joseph JS, et al. Long-term remission rates after splenectomy in adults with Evans syndrome compared to immune thrombocytopenia: A single-center retrospective study. Eur J Haematol 104: 55-58, 2020.","DOI":"10.1111\/ejh.13336"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Inoue Y, Kosugi S. Successful Treatment of Evans Syndrome With efgartigimod: A Case Report. Am J Ther 2025.","DOI":"10.1097\/MJT.0000000000002066"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 114: 3167-3172, 2009.","DOI":"10.1182\/blood-2009-04-215368"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jiang D, Kuter DJ. Evans syndrome revisited. Blood Rev 74: 101322, 2025.","DOI":"10.1016\/j.blre.2025.101322"},{"key":"13","unstructured":"13. Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 402: 1648-1659, 2023."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kida T, Ozawa T, Takahashi T, et al. Combination therapy with efgartigimod, fostamatinib, eltrombopag and prednisolone for a patient with refractory immune thrombocytopenia. Rinsho Ketsueki 66: 117-120, 2025.","DOI":"10.11406\/rinketsu.66.117"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7519-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:49:02Z","timestamp":1781322542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7519-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":14,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7519-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7519-26"}}